Deb Miller, PhD, JD
Deborah (Deb) Miller, Ph.D., J.D., joined Nuvalent as Chief Legal Officer in June 2021 and is responsible for legal and human resources. She brings more than 20 years of senior leadership and global legal expertise across the entire pharmaceutical lifecycle from early discovery though litigation.
Prior to joining Nuvalent, she most recently served as Senior Vice President, Deputy General Counsel and Chief IP Counsel for Sumitomo Dainippon Pharma America (SDPA), a shared services company supporting affiliates of the Sumitomo Dainippon Pharma Group including Sunovion Pharmaceuticals Inc. and SDP Oncology. At SDPA, she led global IP strategy, IP diligence, as well as various contract dispute matters and business development transactions and was instrumental in building and enforcing global IP portfolios for over 30 oncologic, neurologic, psychiatric, and respiratory products, including LATUDA®, KYNMOBI®, APTIOM®, and LONHALA® MAGNAIR®.
Earlier in her career, Deb served as Deputy General Counsel and Chief Patent Counsel at Infinity Pharmaceuticals where she was responsible for developing the IP strategy of various oncology products and helped secure multiple strategic partnerships. In addition, she served as Corporate Counsel at Sepracor (now Sunovion) where she managed the litigation of LUNESTA® and developed the IP for various CNS and respiratory products. She began her legal career in private practice at Nutter McClennen & Fish.
Deb earned her Bachelor’s degree in chemistry from Swarthmore College, Master’s in Medical Sciences from Harvard Medical School, Ph.D. in biological chemistry and molecular pharmacology from Harvard University, and J.D. from Suffolk University Law School.